PF-06372865 in Subjects With Photosensitive Epilepsy

• Drug: PF-06372865
  
  Single dose
• Drug: Placebo
  
  Placebo for PF-06372865 and placebo for lorazepam
• Drug: Lorazepam
  
  2 mg single oral dose

• Experimental: PF-06372865 dose level 1
  
  17.5 milligram (mg) single dose
  Intervention: Drug: PF-06372865
• Experimental: PF-06372865 dose level 2
  
  52.5 mg single dose
  Intervention: Drug: PF-06372865
• Placebo Comparator: Placebo
  
  Single dose
  Intervention: Drug: Placebo
• Active Comparator: Lorazepam
  
  2mg single dose
  Intervention: Drug: Lorazepam

Inclusion Criteria:

• A diagnosis and history of photoparoxysmal response on electroencephalogram (EEG) with or without a diagnosis of epilepsy for which subjects are taking up to 0 - 2 concomitant antiepileptic drugs.
• Subjects currently taking antiepileptic drug(s) to be on a stable dose for 4 weeks prior to Screening Visit.
• A minimum average standardized photosensitive range (SPR) across all screening timepoints of 4 in the most sensitive eye condition and a non-zero average in at least one other eye condition.

Exclusion Criteria:

• Subjects with a history of status epilepticus.
• Subjects who have experienced a generalized tonic-clonic convulsion in the past 6 months, at the time of the initial screening visit.